News Gallery

Gates Foundation Africa highlights socioeconomic conditions underpinning HIV and TB

This film project from Gates Foundation Africa highlights the socioeconomic conditions that underpin HIV and TB. The series documents the sometimes harrowing stories of South Africans who are managing their health conditions in the face of complex and multilayered challenges.

UNAIDS Executive Director Michael Sidibé on World AIDS Day 2018

The theme of this year's World AIDS Day is "Live life positively: Know your HIV status". In this video, Michael Sidibé, UNAIDS Executive Director, explains the importance of testing:

Take the UNAIDS "Test Test" if you are unsure if you are at risk of HIV infection.

PredART trial results published in New England Journal of Medicine

An analysis published in the New England Journal of Medicine shows that a four-week course of moderate dose prednisone reduces the risk of TB-IRIS (tuberculosis-associated immune reconstitution inflammatory syndrome) by 30% in HIV-positive patients at high risk of developing the condition. This is the first trial to show that TB-IRIS can be prevented in these patients and represents an important contribution to the body of knowledge on management of HIV-TB co-infection. The findings have already resulted in changes to antiretroviral therapy guidelines around the world. 

In the PredART trial, researchers from CIDRI-Africa and the Institute of Tropical Medicine (Antwerp, Belgium) investigated whether providing people at high risk of TB-IRIS with moderate-dose prednisone could prevent development of the condition. The researchers enrolled HIV-positive patients who were initiating ART, who had started tuberculosis treatment within 30 days before enrolment, and who had a very low CD4 count

Watch a video on the trial below.

Union Scientific Director comments on M72 vaccine trial

Following the recent International Union against Tuberculosis and Lung Disease World Conference, Scientific Director Dr Paula Fujiwara commented on several new TB-related innovations, including the M72 vaccine trial in which CIDRI-Africa participated.

Visit by delegation from the People's Republic of China